CVS PBM Specialty Drug Sales Rise 53% On New Business In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Although strong demand for Gilead’s hepatitis C drug Sovaldi contributed to the increase, “it was not the lion’s share of the growth,” CEO Larry Merlo said.